Carcinoma, Non-Small-Cell Lung Clinical Trial
Official title:
The Drainage Effect of a Chest Tube Plus Prophylactic Air-extraction Catheter vs Traditional Drainage Strategy in Uniportal Upper Lung Lobectomy
Traditional drainage for uniportal video assisted thoracoscopic surgery (VATS) is a routine
method, usually with one or two chest tubes at intercostal incisions, but postoperative pain
due to the chest tube and unsatisfied drainage effect was noted.
In this study, the investigators are going to explore whether a prophylactic air-extraction
catheter combined with chest tube drainage may not increase complications in uniportal VATS
for upper lung lobectomy. The patients would be assigned to two arms, one with a prophylactic
air-extraction catheter combined with chest tube, and another with two chest tubes, and the
effect of the combined drainage strategy will be evaluated.
Research purpose and background:
Surgical resection is still one of the most important treatment methods for early stage
non-small cell lung cancer. Complete resection and reasonable dissection of mediastinal lymph
nodes are the key of cancer cure. Lobectomy has always been the standard surgical method for
lung cancer radical resection. It can remove the lesion and retain normal lung function by
resecting the lung lobe where the lesion is and preserve the remaining lobe. In recent years,
the development of uniport video-assisted thoracic surgery (VATS) has further reduced the
trauma, with treatment benefit similar with that of two-port and three-port thoracoscopy.
However, based on the single hole thoracoscopic lung recruitment, incision drainage and other
issues also need further evidence support.
No tube technology, such as no tracheal intubation, drainage tube, nor catheter combined with
video-assisted thoracoscopy, can significantly improve the rehabilitation of patients, and
further shorten the postoperative hospital stay. In addition, the safety of tubeless drainage
has been supported by more and more studies. However, poor drainage may also increase the
incidence of pneumothorax and postoperative pulmonary dysfunction.
After upper lobe lobectomy, the cavity needs to be filled by the full recruitment of the
remaining lobes. theoretically, there is a higher demand for the strategy of the drainage
tube. The investigatorstried to compare the safety and effectiveness of the prophylactic
air-extraction catheter (later known as microtubule) combined with thoracic tube drainage
with traditional double drainage tube alone. Therefore, the investigators conducted a
prospective, randomized, non inferiority trial to verify the hypothesis that microtubule
combined with thoracic catheter drainage after uniport VATS upper lobectomy will not increase
the related perioperative complications compared with traditional thoracic tube drainage.
Quality assurance plan:
1. The doctors participating in the operation and catheterization in clinical trials should
be at least attendings, so as to ensure the safety of operation and chest tube
placement.
2. The chest tube placement was carried out randomly with two arms.
3. From our previous clinical experience, the tube is placed for 3 days to 2 weeks, so it
last for a short time, and all of them can be extubated by doctors above the attending
level, so the detachment rate of the experiment is low and the quality can be
guaranteed.
4. The trial team has written the test related procedures into the team medical process,
including but not limited to the time point of chest X-ray.
Data checks:
Data checks will be performed by a individual attending doctor with GCP to compare data
entered into the registry against predefined rules for range or consistency with other data
fields in the registry.
Source data verification:
Source data verification will be performed by a individual attending doctor with GCP to
assess the accuracy, completeness, or representativeness of registry data by comparing the
data to external data sources (for example, medical records, paper or electronic case report
forms, or interactive voice response systems).
Data dictionary:
video assisted thoracoscopic surgery, VATS prophylactic air-extraction catheter, PAEC
Randomized clinical trial, RCT Non small cell lung cancer, NSCLC
Standard Operating Procedures:
Patients recruitment The subjects were recruited on a voluntary basis. If they decide to
participate in this study, the personal data of subjects participating in the trial are
confidential. The subject's blood samples will be identified by the study number, not the
subject's name. Information that identifies the subject will not be disclosed to members
outside the study team unless permission is obtained from the subject. All study members and
study sponsors were asked to keep their identities confidential. The subjects' files will be
kept in a locked file cabinet for researchers' reference only. In order to ensure that the
study is carried out in accordance with the regulations, members of the government
administration or the ethics review committee may access the subject's personal data in the
research unit as required. At the time of publication, no personal information will be
disclosed.
data collection All the patients learned about the two kinds of operation through
preoperative education, and voluntarily joined the research group and signed the ethical
agreement. In this clinical trial, patients were enrolled in the randomized controlled trial.
The members of the experimental group were only responsible for the inclusion and exclusion
of patients. The surgeons and assistants did not participate in the preoperative evaluation
and postoperative management. The pain assessment team, postoperative management personnel
and follow-up evaluators did not know what group the patients belonged to (patients could
wear wide clothes to cover the drainage tube after operation)
change management In cases with serious medical risk caused by the operation technology of
the trial, or the research indicates that the difference between the groups is too obvious,
the researcher should stop the trial and fill in the report form of violation of protocol
deviation and report to the ethics committee.
If the patients were enrolled normally and reached the number of cases required for the
trial, the trial was finished.
reporting for adverse events
1. The sponsor shall provide the safety research data of the technology and other safety
related information.
2. In the design scheme, the definition of adverse events should be clearly defined, and
the criteria for judging the severity of adverse events, as well as the classification
criteria for judging the relationship between adverse events and experimental operation
(such as positively related, possibly related, possibly unrelated, irrelevant and unable
to be determined). The protocol requires researchers to truthfully fill in the adverse
event record form, recording the occurrence time, severity, duration, measures taken and
outcome.
3. Before starting the trial, the members of the research team must be familiar with the
contents of the prevention and treatment of subjects and emergency plans in medical
treatment.
4. In case of SAE, the research physician must report to the project leader, the food and
drug administration, the sponsor, the medical ethics committee of our hospital, the
center ethics, and the office of drug clinical trial institution within 24 hours. When
and by what means (e.g. telephone, fax or written) to whom SAE was reported should be
recorded in the original data.
5. The original medical ethics committee reports the paper version, including the receipt
page (with PI signature), SAE form and processing process in triplicate, and then
reports the electronic version of PPT, which is then sent to wangxing5447@126.com
6. To study the doctor according to the implementation of treatment, if necessary, start to
prevent and deal with medical subjects and emergency plans.
7. At the same time, the research doctor should make a record of SAE, including at least
the description of adverse events, occurrence time, termination time, degree and
frequency of seizures, and the treatment given.
8. The medical ethics committee will hold a meeting to organize experts to report and
discuss the SAE and the treatment process in our hospital, and require the follow-up of
SAE.
Sample size assessment
The purpose of this study was to verify whether the new strategy is not inferior to
traditional method in uniport VATS upper lobe lobectomy. In terms of the incidence of
pneumothorax (primary), based on previous observational studies, the probability of
postoperative pneumothorax in new method and traditional method was about 10% and 6%.
Considering 25% of non-inferiority margin, efficacy analysis estimated that 75 patients in
each group were required to achieve power of 0.99 (via version 15.0; NCSs, Kaysville, UT,
USA) with unilateral α of 0.025. Considering some out of groups due to clinical factors or
other criteria (e.g., changing surgical methods according to pathological results during
operation, combined with other lobectomy, etc.), a total of 75 subjects in each group were
required, and 400 is the anticipating case number.
Plan for missing data The investigators made a plan for missing data to address situations
where variables are reported as missing, unavailable, non-reported, uninterpretable, or
considered missing because of data inconsistency or out-of-range results.
First, sufficient case is planned for the missing data generated from changes in surgery, as
combined lobectomy or sublobectomies. Second, all the surgeons in our department will be
informed of this study, and the changes in surgical method should be avoided to their best
effort.
Statistical analysis plan
Statistical analysis will be performed to these select two groups in terms of clinical
parameters, including the incidence of pneumothorax, reintubation rate, pain score and other
parameters, respectively using t test, chi square test, rank sum test and other means. SPSS
20 will be validated to compare the primary and secondary observation end points between the
two groups.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT04879849 -
A Study of TAK-676 With Pembrolizumab After Radiation Therapy to Treat a Number of Cancers
|
Phase 1 | |
| Completed |
NCT04426825 -
A Study of Atezolizumab in Combination With Bevacizumab in Patients With EGFR Mutation Positive Stage IIIB-IV Non-Squamous Non-Small Cell Lung Cancer
|
Phase 2 | |
| Terminated |
NCT03166631 -
A Trial to Find the Safe Dose for BI 891065 Alone and in Combination With BI 754091 in Patients With Incurable Tumours or Tumours That Have Spread
|
Phase 1 | |
| Completed |
NCT02864394 -
Study of Pembrolizumab Versus Docetaxel in Participants Previously Treated for Non-Small Cell Lung Cancer (MK-3475-033/KEYNOTE-033)
|
Phase 3 | |
| Completed |
NCT02810457 -
Evaluation of FKB238 and Avastin in Patients With Advanced/Recurrent Non-squamous Non-small Cell Lung Cancer
|
Phase 3 | |
| Recruiting |
NCT04592523 -
A Study of Usage of Brigatinib in the Treatment of Adult Participants for Approved Indications In South Korea
|
||
| Recruiting |
NCT04838548 -
A Study to Evaluate the Efficacy and Safety of MRG003 in Patients With EGFR-Positive Advanced Non-Small Cell Lung Cancer
|
Phase 2 | |
| Recruiting |
NCT04077463 -
A Study of Lazertinib as Monotherapy or in Combination With Amivantamab in Participants With Advanced Non-small Cell Lung Cancer
|
Phase 1 | |
| Recruiting |
NCT05167604 -
Clinical Value of MRD Monitoring for Adjuvant Therapy in Postoperative NSCLC
|
||
| Recruiting |
NCT04603807 -
A Study to Compare the Efficacy and Safety of Entrectinib and Crizotinib in Participants With Advanced or Metastatic ROS1 Non-small Cell Lung Cancer (NSCLC) With and Without Central Nervous System (CNS) Metastases
|
Phase 3 | |
| Completed |
NCT04948411 -
Durvalumab as Maintenance in Patients Who Received Chemoradiotherapy for Unresectable Stage III NSCLC: Real World Data From an Expanded Access Program in Brazil
|
||
| Active, not recruiting |
NCT04487080 -
A Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib in Locally Advanced or Metastatic Non-Small Cell Lung Cancer
|
Phase 3 | |
| Not yet recruiting |
NCT04255836 -
Durvalumab Combined With Chemotherapy and Stereotactic Body Radiotherapy (SBRT) in Patients With Oligometastatic Non-small Cell Lung Cancer (NSCLC)
|
Phase 2 | |
| Completed |
NCT01953913 -
Afatinib (BIBW 2992) in Advanced Non-Small Cell Lung Cancer Patients With EGFR Mutation
|
Phase 3 | |
| Recruiting |
NCT05715229 -
Immune Profile Selection By Fraction of ctDNA in Patients With Advanced NSCLC Treated With Immunotherapy
|
Phase 2 | |
| Recruiting |
NCT04931654 -
A Study to Assess the Safety and Efficacy of AZD7789 in Participants With Advanced or Metastatic Solid Cancer
|
Phase 1/Phase 2 | |
| Suspended |
NCT05421936 -
Osimertinib for NSCLC With Uncommon EGFR Mutations
|
||
| Completed |
NCT02847377 -
A Positron Emission Tomography (PET) Imaging Agent [18F]-ODS2004436 as a Marker of EGFR Mutation in Subjects With NSCLC
|
N/A | |
| Completed |
NCT04427072 -
Study of Capmatinib Efficacy in Comparison With Docetaxel in Previously Treated Participants With Non-small Cell Lung Cancer Harboring MET Exon 14 Skipping Mutation
|
Phase 3 | |
| Recruiting |
NCT04823377 -
Impact of a Process Optimizing the Decision to Continue or Stop Cancer Treatments in Patients With Advanced Non-small Cell Lung Cancer.
|
N/A |